恶性造血细胞中P-gp170表达的比较研究(英文)  

Comparative study on expressions of P-gp170 in malignant hematopoietic cells

作　　者：夏国华[1] 陈宝安[2] 邵泽叶[1] Dohner Konstanze Dohner Hartmut 

机构地区：[1]东南大学临床医学院,江苏南京210009 [2]东南大学附属中大医院血液科,江苏南京210009 [3]乌尔姆大学医学院,德国乌尔姆89081

出　　处：《东南大学学报（医学版）》2006年第6期391-396,共6页Journal of Southeast University(Medical Science Edition)

基　　金：National Natural Science Foundation(No.00-R-318).

摘　　要：目的:通过研究恶性造血细胞中P-糖蛋白(P-gp)170的表达,为骨髓增生异常综合征(MDS)治疗提供P-gp 170低表达的体外细胞株模型。方法:用含0.1 mmol.L-1阿霉素的RPM I 1640分别培养MDS细胞株MUTZ-1和多药耐药(MDR)红白血病细胞株K562/A02。用MTT法检测细胞的增殖抑制作用,光镜和电镜技术分别观察与阿霉素共同培养后的MUTZ-1细胞和K562/A02细胞形态和超微结构,流式细胞仪分别测定MUTZ-1细胞和K562/A02细胞P-gp 170表达水平。结果:0.1 mmol.L-1阿霉素对MUTZ-1细胞增殖呈时间依赖性抑制作用,而对K562/A02细胞的增殖没有影响;MUTZ-1细胞出现典型的凋亡形态学改变,K562/A02细胞表面呈现出许多长的微绒毛和许多微孔;K562/A02细胞与MUTZ-1细胞相比高表达P-gp 170。结论:P-gp 170在恶性造血细胞中表达有显著性差异,P-gp 170低表达的MUTZ-1细胞株可用于MDS治疗的体外研究模型,P-gp 170高表达的K562/A02细胞株可用于MDR逆转的体外研究模型。Objective To investigate the expression of P-glycoprotein （P-gp） 170 in malignant hematopoietic cells, and to provide a model with low expression of P-gp 170 in vitro suitable for myelodysplastic syndrome optimal therapy. Methods Myelodysplastic syndrome cell line（ MUTZ-1 ） and a multidrug-resistance（MDR） erythroleukemia cell line（K562/A02） were cultured in medium of RPMI 1640 with 0.1 mmol · L^-1 adriamycin,respectively. The cell viability and cytotoxity were confirmed through MTT assay, the cell morphology was identified with optical microscope and observed under transmission electron microscope,and the P-gp 170 levels in MUTZ- 1 and K562/A02 cells were detected by flow cytometry. Results O. 1 mmol · L^-1 adriamycin inhibited the proliferation of MUTZ-1 cells in a time-dependent manner and had no influence on K562/A02 cells; MUTZ-1 cells showed characteristic apoptotic morphology, while K562/A02 cells presented numerous long microvilli and lots of foramen and high expression of P-gp 170 as compared to sensitive MUTZ-1 cells. Conclusions Expression of P-gp 170 has remarkable difference in malignant hematopoietic cells. MUTZ-1 cell line is a suitable model for myelodysplastic syndrome optimal therapy in vitro, and K562/A02 cell line is a suitable model for studying the reversion of multidrug-resistance in vitro.

关 键 词：P-糖蛋白170 恶性造血细胞 MUTZ-1细胞株 K562/A02细胞株 骨髓增生异常综合征 多药耐药 

分 类 号：R551.3[医药卫生—血液循环系统疾病] Q591.2[医药卫生—内科学]